Download Sample
Add to CartGlobal Pertussis Infection Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product Type;
Reagents & Kits, Bordetella Pertussis IgM ELISA Test, Instruments, FluoroType Bordetella, and PCR Instruments.By Diagnosis;
Blood Tests, Chest X-Ray, Nose or Throat Culture Test, and Other Diagnosis Types.By End Users;
Hospitals, Specialty Clinics, Diagnostic Laboratories, and Research Centers.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Pertussis Infection Testing Market (USD Million), 2021 - 2031
In the year 2024, the Global Pertussis Infection Testing Market was valued at USD 326.63 million. The size of this market is expected to increase to USD 491.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.
The global pertussis infection testing market is experiencing significant expansion, driven by the rising need for accurate and efficient diagnostic tools to combat pertussis, commonly known as whooping cough. This highly contagious respiratory illness, caused by the Bordetella pertussis bacterium, primarily impacts infants, young children, and individuals with weakened immune systems. Despite widespread immunization efforts, pertussis remains a persistent global health threat, with outbreaks frequently occurring in regions where vaccination coverage dips below 90%. Growing concerns about disease burden and awareness of potential complications are fueling the demand for rapid, reliable diagnostic solutions.
One of the key factors propelling market growth is the urgent need for early and precise diagnosis. Pertussis symptoms, such as persistent coughing and breathing difficulties, closely mimic other respiratory illnesses like influenza, making timely and accurate testing essential. Healthcare providers now rely on a variety of diagnostic methods, including traditional culture techniques, polymerase chain reaction (PCR) tests, serological assays, and rapid antigen detection tests. Among these, PCR testing dominates the market, accounting for approximately 55% of all pertussis diagnostic procedures, thanks to its superior sensitivity and fast results that significantly improve early detection rates.
Technological advancements are playing a pivotal role in shaping the pertussis testing landscape. Modern PCR-based diagnostics boast a detection sensitivity exceeding 95%, making them the preferred choice for early-stage infection identification. Meanwhile, point-of-care (POC) testing solutions are rapidly gaining momentum, currently representing around 20% of the total market, as healthcare providers seek faster, decentralized testing options. Additionally, the growing trend towards home-based diagnostic kits is broadening market reach by offering more accessible and convenient testing for consumers.
Global investments in healthcare infrastructure and diagnostic laboratory capabilities are further bolstering the pertussis infection testing market. Government initiatives aimed at enhancing vaccination programs and strengthening disease surveillance—especially in areas where immunization rates fall below 80%—are making efficient diagnostic testing more critical than ever. With ongoing technological innovations, strong public health strategies, and increasing global awareness, the pertussis infection testing market is set for sustained, long-term growth.
Global Pertussis Infection Testing Market Recent Developments
-
In July 2023, the price of Quadracel, a DTaP-IPV vaccine developed by Sanofi Pasteur—the vaccine division of French pharmaceutical giant Sanofi—was set at USD 61.12 per single vial. This pricing reflects the premium positioning of combination vaccines in the immunization market. Additionally, emerging markets are creating lucrative growth opportunities for leading players in the pertussis vaccine market, driven by increasing healthcare investments, rising awareness about immunization programs, and government-led vaccination initiatives.
-
In June 2021, GSK outlined a strategic plan to drive substantial growth and enhance overall performance by prioritizing research and development efforts. The company also committed to boosting commercial investments specifically in its vaccines and specialty medicines segments, reinforcing its focus on innovation and expanding market presence.
Segment Analysis
In this report, the Global Pertussis Infection Testing Market has been segmented by Product Type, by Dignosis, End Users, and Geography.
Global Pertussis Infection Testing Market, Segmentation by Product Type
The Global Pertussis Infection Testing Market has been segmented by Product Type into Reagents and Kits, Bordetella Pertussis IgM ELISA Test, Instruments, FluoroType Bordetella and PCR Instruments.
The Global Pertussis Infection Testing Market is categorized by Product Type into several primary segments, including Reagents and Kits, Bordetella Pertussis IgM ELISA Tests, Instruments, FluoroType Bordetella, and PCR Instruments. Among these, the Reagents and Kits segment leads the market, holding approximately 45% of the global share. These components are essential for a variety of diagnostic procedures such as PCR assays, ELISA tests, and antigen detection methods, all of which are critical for accurate and timely diagnosis of pertussis. The increasing demand for rapid, high-precision testing solutions continues to drive the need for premium-quality reagents and kits. As healthcare facilities and diagnostic laboratories scale up their testing infrastructure, the growth trajectory of this segment is expected to remain strong.
The Bordetella Pertussis IgM ELISA Test segment also captures a substantial portion of the market, contributing nearly 25% to the overall share. This diagnostic method targets the detection of IgM antibodies specific to Bordetella pertussis, making it particularly valuable for diagnosing infections in their later stages. The test is highly regarded for its sensitivity and effectiveness in identifying past infections, and it is often utilized in regions with high vaccination rates. However, because IgM ELISA tests have limited effectiveness in detecting early-stage infections, they are frequently used alongside PCR-based molecular diagnostics to ensure comprehensive and accurate pertussis detection.
Meanwhile, the Instruments segment, encompassing both FluoroType Bordetella and PCR Instruments, is witnessing robust expansion, representing roughly 30% of the global market. Innovative technologies such as FluoroType Bordetella leverage fluorescence-based PCR techniques to deliver rapid and highly accurate detection of Bordetella pertussis DNA. These advanced solutions offer quicker results compared to traditional PCR methods while maintaining high sensitivity and specificity. PCR Instruments continue to be indispensable tools for early-stage diagnosis, especially for detecting infections in asymptomatic individuals. The growing adoption of molecular diagnostic platforms in clinical laboratories, coupled with the rising demand for early and reliable pertussis diagnosis, is fueling substantial growth in this segment.
Global Pertussis Infection Testing Market, Segmentation by Diagnosis
The Global Pertussis Infection Testing Market has been segmented by Diagnosis into Blood Tests, Chest X-Ray, Nose or Throat Culture Test, and Other Diagnosis Types.
Blood Tests: Leading the Diagnostic Segment
Blood tests dominate the pertussis infection testing market by diagnosis type, accounting for approximately 45% of the global share. Blood tests, particularly serological assays detecting IgM and IgG antibodies against Bordetella pertussis, are critical for confirming recent or past infections. These tests are highly valued for their accuracy in cases where symptoms may be atypical or mild, especially among vaccinated individuals. Their ability to support rapid screening and complement molecular diagnostics has made blood tests a preferred choice across hospitals, diagnostic laboratories, and specialty clinics worldwide.
Chest X-Ray: Supporting Clinical Assessment
Chest X-ray diagnostics represent about 20% of the market share within pertussis diagnosis. Although not used to directly detect Bordetella pertussis, chest X-rays are crucial in identifying lung inflammation or complications arising from pertussis infections, such as pneumonia. Physicians often recommend chest X-rays when severe respiratory symptoms are present, helping differentiate pertussis from other respiratory illnesses. The demand for chest X-rays in pertussis diagnosis is expected to remain steady, particularly in settings where advanced laboratory testing is not immediately available.
Nose or Throat Culture Test: Traditional yet Reliable
Nose or throat culture tests contribute around 25% to the overall diagnostic segment. These traditional methods involve collecting a sample from the nasopharynx and culturing it to detect the presence of Bordetella pertussis. Although the process takes longer—typically several days—culture testing is still considered the gold standard for definitive pertussis diagnosis in certain cases. It is especially important in epidemiological studies and outbreak investigations where high specificity is critical. Advances in transport media and culture techniques have slightly improved the turnaround time, maintaining relevance for culture testing in modern clinical settings.
Other Diagnosis Types: Emerging Innovations
Other diagnosis types, including rapid antigen detection tests and emerging molecular diagnostic innovations, make up the remaining 10% of the market. Rapid diagnostic tests offer faster results, typically within a few hours, and are increasingly deployed in point-of-care (POC) settings. Newer molecular techniques, such as multiplex PCR panels, are also gaining traction for their ability to simultaneously detect multiple respiratory pathogens, including pertussis. The growing need for quick and accurate diagnostic solutions, especially in resource-limited environments, is expected to boost the share of these emerging diagnostic methods in the coming years.
Global Pertussis Infection Testing Market, Segmentation by End Users
The Global Pertussis Infection Testing Market has been segmented by End Users into Hospitals, Specialty Clinics, Diagnostic Laboratories and Research Centers.
Hospitals: Dominating the End-User Segment
Hospitals account for approximately 50% of the global pertussis infection testing market by end users, making them the largest segment. Their dominance is attributed to their robust infrastructure, access to skilled healthcare professionals, and advanced diagnostic equipment. Hospitals are typically the first point of care for patients with suspected pertussis infections, especially in severe cases involving infants or immunocompromised individuals. With access to a full range of diagnostic tests—including PCR assays, serological tests, and rapid antigen detection—hospitals ensure accurate and timely diagnosis. The increasing investment by hospitals in cutting-edge diagnostic technologies aimed at improving detection rates is expected to further fuel growth in this segment.
Specialty Clinics: Rising Role in Pertussis Diagnosis
Specialty clinics contribute nearly 25% of the pertussis infection testing market share among end users. These clinics, particularly those focusing on pediatrics, respiratory care, and infectious diseases, play a crucial role in diagnosing and managing pertussis, especially among high-risk groups such as infants, the elderly, and pregnant women. Specialty clinics offer rapid diagnostic services using PCR-based assays and rapid antigen detection tests, enabling early intervention and treatment. The growing emphasis on pediatric healthcare and the increasing incidence of pertussis infections in vulnerable populations are expected to boost demand for pertussis testing services in specialty clinic settings.
Diagnostic Laboratories: Ensuring Comprehensive Testing Solutions
Diagnostic laboratories, including commercial labs and academic research institutions, hold about 20% of the market share. These facilities are pivotal in offering high-quality, reliable testing using advanced technologies such as PCR instruments, IgM ELISA tests, and traditional culture-based methods. As healthcare providers and public health agencies intensify their surveillance of respiratory diseases, the demand for comprehensive pertussis testing through diagnostic laboratories is surging. The laboratories' capacity to deliver large volumes of accurate results plays an essential role in supporting public health initiatives and outbreak management strategies.
Research Centers: Driving Innovation in Diagnostics
Although smaller in market share, accounting for approximately 5%, research centers play an outsized role in shaping the future of the pertussis infection testing market. These institutions focus on developing new diagnostic technologies, refining existing methods, and studying the epidemiology of Bordetella pertussis. Research centers contribute significantly to innovations such as faster PCR techniques, improved antigen detection methods, and novel vaccine development. Their contributions are vital for enhancing diagnostic accuracy, enabling earlier detection, and ultimately supporting global efforts to reduce pertussis-related morbidity and mortality.
Global Pertussis Infection Testing Market, Segmentation by Geography
In this report, the Global Pertussis Infection Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Pertussis Infection Testing Market Share (%), by Geographical Region, 2024
The Global Pertussis Infection Testing Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
North America: Leading the Global Market
North America holds the largest share of the global pertussis infection testing market, accounting for approximately 40% of the overall revenue. The market’s dominance is fueled by advanced healthcare infrastructure, high public awareness regarding pertussis, and the presence of leading diagnostic companies. The United States is the major growth driver, supported by widespread vaccination campaigns, a relatively high incidence of pertussis among infants and elderly populations, and the rapid adoption of advanced diagnostics such as PCR assays and ELISA tests. The region’s robust healthcare system, coupled with the widespread availability of molecular diagnostic tools in hospitals and specialty clinics, continues to boost market expansion.
Europe: Strong Focus on Early Detection and Vaccination
Europe represents approximately 30% of the global pertussis infection testing market. Growth in this region is driven by strong healthcare systems, rigorous regulatory standards, and increasing governmental efforts to raise vaccination coverage and enhance disease surveillance. Major economies like Germany, the United Kingdom, and France are spearheading advancements, with many healthcare institutions incorporating advanced diagnostic techniques such as PCR-based testing. Supportive initiatives from the European Union to monitor infectious diseases and the heightened demand for accurate diagnostic solutions are key factors propelling the market forward across Europe.
Asia Pacific: Fastest Growing Regional Market
The Asia Pacific region is poised to achieve the fastest growth rate in the global pertussis infection testing market, expected to grow at a compound annual growth rate (CAGR) of over 8% during the forecast period. Countries like China, India, and Japan are leading this growth, driven by rising healthcare investments, an increasing burden of pertussis, and better access to modern diagnostic technologies. Factors such as rapid urbanization, greater healthcare awareness, and expanding healthcare infrastructure are significantly boosting adoption rates of pertussis testing across the region. As diagnostic capabilities continue to improve, Asia Pacific is set to emerge as a major contributor to global market revenues.
Middle East, Africa, and Latin America: Emerging Markets with Steady Growth
The Middle East and Africa and Latin America collectively contribute around 15% of the global pertussis infection testing market. Although these regions currently experience moderate growth compared to North America and Asia Pacific, ongoing improvements in healthcare access, public health initiatives, and infectious disease control programs are gradually strengthening their market presence. Economic challenges and historically lower vaccination rates have somewhat limited progress; however, a growing focus on disease surveillance and expanding availability of diagnostic technologies are expected to fuel future demand. As healthcare infrastructures in these regions continue to develop, opportunities for pertussis infection testing providers are expected to steadily increase.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Pertussis Infection Testing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Rising Incidence of Pertussis Outbreaks
- Demand for Early and Accurate Diagnosis
-
Advancements in Diagnostic Technologies- The Global Pertussis Infection Testing Market is being driven by advancements in diagnostic technologies, which have significantly enhanced the ability to detect pertussis more accurately and efficiently. Over the past few years, there has been a shift toward more rapid and precise testing methods. The introduction of polymerase chain reaction (PCR) technology has been a game-changer in pertussis diagnosis. PCR allows for the detection of Bordetella pertussis DNA in patient samples, even in the early stages of infection when traditional diagnostic methods, such as culture tests, might fail to detect the pathogen. PCR-based tests are highly sensitive and specific, enabling clinicians to diagnose pertussis quickly and with greater accuracy, which is crucial for effective treatment and reducing transmission.
In addition to PCR, molecular diagnostics such as FluoroType Bordetella have emerged as another significant advancement. This technology utilizes fluorescence-based PCR techniques, offering even faster results compared to traditional PCR, making it ideal for point-of-care (POC) settings. These innovations have improved the turnaround time for results, allowing for quicker diagnosis, which is particularly important in hospitals and emergency settings where time-sensitive decisions are necessary. The ability to conduct tests more rapidly also facilitates better patient management and reduces the burden on healthcare systems, making diagnostic procedures more efficient and less expensive over time.
The growing adoption of serological tests and rapid antigen detection tests has also contributed to advancements in pertussis diagnosis. While these methods are not as sensitive as PCR, they offer several advantages, such as affordability, simplicity, and the ability to be used in remote or resource-limited areas. These tests can quickly detect antibodies or antigens related to Bordetella pertussis in patients, providing valuable information for epidemiological surveillance and outbreak management. The continued innovation and refinement of these diagnostic technologies ensure that healthcare providers have a wider array of tools at their disposal to detect pertussis more effectively, ultimately driving the growth of the pertussis infection testing market. As these technologies continue to evolve, they will likely make testing even more accessible, improving both the speed and accuracy of pertussis diagnoses across various healthcare settings.
Restraints:
- High Cost of Advanced Diagnostic Tests
- Lack of Standardization in Diagnostic Methods
-
Shortage of Skilled Labor and Infrastructure in Developing Regions- The growth of the Global Pertussis Infection Testing Market faces significant barriers due to a shortage of skilled labor and inadequate healthcare infrastructure in developing regions. Many low- and middle-income countries struggle to build and sustain the necessary systems required for advanced diagnostic testing. Although molecular diagnostic technologies such as PCR assays and serological tests have transformed pertussis detection, these methods demand specialized equipment and highly trained personnel. Unfortunately, healthcare systems in several developing areas often lack sufficient laboratory facilities, diagnostic tools, and funding, leading to delays in the timely identification and treatment of pertussis infections. Consequently, the adoption of advanced testing technologies in these regions lags behind that of developed markets, hindering market expansion.
The shortage of skilled labor further compounds the issue. Conducting accurate pertussis testing—particularly through PCR and other molecular diagnostic techniques—requires trained laboratory technicians and healthcare professionals proficient in operating complex diagnostic instruments and interpreting results. However, a significant gap in properly trained professionals exists across many developing countries. Issues such as brain drain, where qualified healthcare workers migrate to developed nations for better career prospects, worsen the shortage. This lack of expertise often results in suboptimal test quality, misdiagnosis, or the complete absence of available diagnostic services. Without sufficient skilled labor, the ability to deliver accurate, timely pertussis diagnoses diminishes, limiting effective intervention strategies and slowing the overall growth of the pertussis infection testing market in these regions.
Inadequate healthcare infrastructure, particularly in rural and remote areas, presents another major challenge. Even in countries with advanced urban medical facilities, rural regions often experience limited access to pertussis diagnostic tests. The absence of necessary elements such as diagnostic laboratories, reliable power supplies, and proper cold-chain systems for reagent storage makes widespread testing difficult. These infrastructure deficiencies not only impact the use of complex molecular diagnostics but also hinder the deployment of more accessible alternatives like rapid antigen detection tests and point-of-care (POC) diagnostic solutions. As a result, the growing burden of pertussis infections in underserved regions remains unmet by sufficient diagnostic capabilities, reducing the impact of technological innovations and slowing global market growth. Addressing the infrastructure and workforce shortages will be critical to unlocking the full potential of the pertussis infection testing market in developing areas.
Opportunities:
- Growth in Point-of-Care (POC) and Home-Based Testing Solutions
- Technological Innovations in PCR and Molecular Testing
-
Increase in Vaccination and Monitoring Programs- The growth of the Global Pertussis Infection Testing Market is strongly driven by the rise in vaccination campaigns and enhanced disease monitoring programs aimed at controlling pertussis outbreaks and improving public health surveillance. As governments and healthcare organizations increasingly recognize the critical need to prevent pertussis, there has been a notable push for comprehensive vaccination efforts targeting infants, adolescents, and vulnerable populations. These expanded vaccination initiatives not only help lower the incidence of pertussis but also heighten public awareness about the disease, consequently fueling the demand for accurate diagnostic testing. As vaccination rates improve, there is greater emphasis on tracking vaccine effectiveness and identifying emerging outbreaks, boosting the need for efficient and reliable diagnostic solutions to detect the presence of Bordetella pertussis across different communities.
The expansion of national and international surveillance programs is creating significant growth opportunities for the pertussis infection testing market. Countries worldwide are adopting more rigorous disease monitoring systems, integrating routine screening for pertussis both in clinical environments and during broader epidemiological studies. This surge in surveillance efforts enables early detection of outbreaks and rapid intervention by health authorities, underscoring the critical role of diagnostic testing in modern public health strategies. Especially in regions where vaccination coverage remains suboptimal or where pertussis outbreaks are frequent, the increasing scope of monitoring initiatives is driving steady demand for accurate and scalable testing methods.
Moreover, the growing focus on surveillance is fostering innovation in diagnostic technology. Governments and public health bodies are increasingly collaborating with diagnostic companies to develop cost-effective, rapid, and point-of-care (POC) solutions that can be deployed in resource-limited settings. Advances such as rapid antigen tests, molecular diagnostics, and digital health platforms are opening new avenues for real-time disease tracking and more accessible diagnostic services. The integration of diagnostic testing within vaccination and monitoring frameworks ensures that testing becomes a routine part of public health management, extending its reach beyond traditional clinical settings. This synergistic relationship between vaccination drives, disease surveillance, and diagnostic innovations will continue to be a major catalyst for the growth of the pertussis infection testing market, particularly in regions with high disease burdens or expanding immunization programs.
Competitive Landscape Analysis
Key players in Global Pertussis Infection Testing Market include,
- Thermo Fisher Scientific, Inc.
- BioMérieux SA
- Abbott Laboratories
- Cepheid (Danaher Corporation)
- Hologic, Inc.
- Quidel Corporation
- Meridian Bioscience, Inc.
- Becton, Dickinson and Company (BD)
- Roche Diagnostics
- DiaSorin S.p.A.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Diagnosis
- Market Snapshot, By End Users
- Market Snapshot, By Region
- Global Pertussis Infection Testing Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising Incidence of Pertussis Outbreaks
- Demand for Early and Accurate Diagnosis
- Advancements in Diagnostic Technologies
- Restraints
- High Cost of Advanced Diagnostic Tests
- Lack of Standardization in Diagnostic Methods
- Shortage of Skilled Labor and Infrastructure in Developing Regions
- Opportunities
- Growth in Point-of-Care (POC) and Home-Based Testing Solutions
- Technological Innovations in PCR and Molecular Testing
- Increase in Vaccination and Monitoring Programs
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Pertussis Infection Testing Market, By Product Type, 2021 - 2031 (USD Million)
- Reagents & Kits
- Bordetella Pertussis IgM ELISA Test
- Instruments
- FluoroType Bordetella
- PCR Instruments
- Global Pertussis Infection Testing Market, By Diagnosis, 2021 - 2031 (USD Million)
- Blood Tests, Chest X-Ray
- Nose or Throat Culture Test
- Other Diagnosis Types
- Global Pertussis Infection Testing Market, By End Users, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Research Centers
- Global Pertussis Infection Testing Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Pertussis Infection Testing Market, By Product Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific, Inc.
- BioMérieux SA
- Abbott Laboratories
- Cepheid (Danaher Corporation)
- Hologic, Inc.
- Quidel Corporation
- Meridian Bioscience, Inc.
- Becton, Dickinson and Company (BD)
- Roche Diagnostics
- DiaSorin S.p.A.
- Company Profiles
- Analyst Views
- Future Outlook of the Market